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Prospective randomized study evaluating
an absorbable cyanoacrylate for use in
vascular reconstructions
Alan B. Lumsden, MD,a and Eugene R. Heyman, PhD,b on behalf of the Closure Medical Surgical
Sealant Study Group, Houston, Tex; and Montgomery Village, Md
Background: An easy-to-use vascular sealant with good safety and efficacy is needed to prevent anastomotic bleeding in
vascular surgery. This study evaluated the safety and efficacy of cyanoacrylate surgical sealant in establishing hemostasis
of expanded polytetrafluoroethylene to arterial vascular anastomoses in arteriovenous (AV) grafts and femoral bypass
grafts.
Methods: This multicenter, randomized, controlled, open-label study was conducted in a hospital setting at 12 sites: 10 in the
United States and 2 in Europe. A total of 151 patients undergoing femoral bypass procedures or AV shunt procedures for
hemodialysis access using expanded polytetrafluoroethylene grafts were randomized 2:1 to receive cyanoacrylate surgical
sealant or the control (oxidized cellulose) between April 26, 2004, and January 18, 2005. Randomization was stratified by
clinical site and type of procedure. After the anastomosis, cyanoacrylate surgical sealant or the control was applied to all
anastomosis sites for patients undergoing femoral bypass procedures and to only the arterial anastomosis sites for patients
undergoing AV shunt procedures. The primary end point was the elapsed time from clamp release to hemostasis. Secondary
end points were the proportion of patients achieving hemostasis at t 0 (immediate), 1, 5, or 10 minutes after clamp release,
use of additional adjunctive measures to achieve hemostasis, and occurrence of adverse events.
Results: Baseline demographics and clinical characteristics showed that the two treatment groups were similar at
baseline. The mean time from clamp release to hemostasis was 119.3 seconds with cyanoacrylate surgical sealant vs
403.8 seconds with the control (P < .001). Immediate hemostasis was achieved in 54.5% of patients receiving
cyanoacrylate surgical sealant and in 10% of those receiving the control. The proportion of patients requiring
additional adjunctive measures was lower with cyanoacrylate surgical sealant, and the occurrence of adverse events
was similar in both groups.
Conclusions:This study demonstrates that cyanoacrylate surgical sealant is effective at reducing the time to hemostasis
and achieving immediate hemostasis in AV shunt and femoral bypass procedures and that it is safe for internal use.
Cyanoacrylate surgical sealant is an easy-to-use vascular sealant with good safety and efficacy that significantly
decreases anastomotic bleeding in vascular surgery. ( J Vasc Surg 2006;44:1002-9.)Bleeding is regarded as a necessary, acceptable byprod-
uct of vascular reconstruction. It is considered to be an
unavoidable consequence of joining an expanded polytet-
rafluoroethylene (ePTFE) graft to an artery. Anastomotic
bleeding, however, can be unpredictable, persistent, and
occasionally limb and life threatening.1 This is of particular
importance for patients in compromised situations, such as
those taking anticoagulants, those with friable vessels, or
those with impaired clot formation. Consequently, a pleth-
ora of sealants and hemostatic agents have been developed
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1002to assist the surgeon in minimizing or controlling anasto-
motic bleeding, and use of these agents is becoming more
widespread in surgical operations.2-4 There are currently
five families of these materials: fibrin sealant, cyanoacrylate,
bovine collagen and thrombin, polyethylene glycol poly-
mer, and albumin cross-linked with glutaraldehyde.5-10
Despite the abundance and variety of these agents, an
easy-to-use vascular sealant with good risk-benefit and cost-
benefit ratios is still not widely available. Such an agent
should be easily applied in a controlled fashion, highly
predictable in creating hemostasis, and nontoxic and must
not have an adverse affect on anastomotic patency. Addi-
tional attributes such as increased anastomotic strength and
the potential to provide drug-delivery opportunities would
also be beneficial.
Nonabsorbable cyanoacrylates for topical use are ap-
proved by the Food and Drug Administration for skin
closure,11,12 but none is currently approved for internal
use. An absorbable cyanoacrylate surgical sealant (Ethicon
OMNEX Surgical Sealant; Closure Medical Corporation,
Raleigh, NC) has been developed that is composed of
2-octyl cyanoacrylate and butyl lactoyl cyanoacrylate. This
sealant polymerizes to form a film that adheres to the tissue
and/or synthetic material, creating a flexible physical seal
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sealant is mechanical and independent of the host coagula-
tion cascade, which should stifle interpatient variability in
clot formation. We have previously reported the results of
our pilot study in which we investigated the use of cyano-
acrylate surgical sealant in 10 patients undergoing arterial
anastomosis of arteriovenous (AV) grafts.13 The study was
designed to gather initial safety and efficacy data to deter-
mine the appropriateness of conducting a larger, multi-
center trial. The mean time from vascular clamp removal to
hemostasis was 9.1  28.8 seconds. Hemostasis was
achieved in 90% (9/10) of patients by 1 minute and in
100% (10/10) of patients by 5 minutes, and no patient
required further adjunctive hemostatic measures. On the
basis of the results of the pilot study, a larger study was
designed to determine the safety and efficacy of cyanoacry-
late surgical sealant in establishing hemostasis of ePTFE to
arterial vascular anastomoses in AV grafts and femoral
bypass grafts. This article reports the results of this large,
randomized, prospective, multicenter trial, which enrolled
151 patients.
METHODS
Patients. Adult patients undergoing femoral-popliteal
bypass or AV shunt procedures for hemodialysis access
using ePTFE vascular grafts were enrolled between April
26, 2004, and January 18, 2005. Patients were excluded for
(1) known hypersensitivity to formaldehyde or cyanoacry-
late, (2) known pregnancy, (3) participation in another
investigational study of a surgical/therapeutic device, drug,
or biologic within the previous 6 months, (4) receiving
anti–vitamin K anticoagulants within 4 days before surgery,
(5) receiving low-molecular-weight heparin within 4 days
before surgery, (6) utilization of gelatin- or collagen-
coated graft material (eg, Vectra Vascular Access Graft;
Thoratec Corporation, Pleasanton, Calif) for femoral by-
pass or AV shunt procedures, and (7) utilization of an
autologous graft for femoral bypass or AV shunt proce-
dures.
Patients were randomized within each investigative site
by type of procedure in a 2:1 randomization by using
blocks of three patients each. Two randomization lists were
created for each site: one for femoral-popliteal bypass pa-
tients and one for AV shunts. After completion of the
anastomosis, patients were randomized to one of two treat-
ment groups, with randomization stratified by the type of
peripheral vascular surgery (femoral bypass or AV shunt).
Oxidized cellulose (Surgicel Absorbable Hemostat; John-
son & Johnson, New Brunswick, NJ), the current standard
of care, was used in patients randomized to receive the con-
trol, and cyanoacrylate surgical sealant (Ethicon OMNEX
Surgical Sealant; Closure Medical Corporation, Raleigh,
NC) was used in patients randomized to receive the inves-
tigational device. Either cyanoacrylate surgical sealant or
the control was placed in a box labeled with the patient
number and procedure and sealed. The boxes were identi-
cal in size and shape, and the content of the box (cyanoac-
rylate surgical sealant or the control) was not indicated onthe outside of the box. The boxes remained sealed until
opened by the operating room staff. Physicians were to
complete suturing the anastomosis before opening the box,
thus eliminating any physician bias that may occur during
the suturing process.
Treatment. At each site, standard practices were used
in the surgical implantation of ePTFE vascular grafts. Sur-
geons were to use a 1:1 needle-thread ratio along the
anastomotic suture line using 5-0 or 6-0 polypropylene
sutures. Cyanoacrylate surgical sealant or the control was
applied to all anastomotic sites for patients undergoing
femoral bypass procedures and was applied to arterial anas-
tomotic sites for patients undergoing AV shunt proce-
dures. For cyanoacrylate surgical sealant, physicians waited
120 seconds before clamp release to allow the sealant to
polymerize. The clamps were then removed, and circula-
tion was restored through the graft. For the control, phy-
sicians were recommended to follow instructions for use.
Treatment sites were observed, and the time from clamp
release to hemostasis was measured with a calibrated stop-
watch. Physicians were allowed to follow the standard of
care for their facility in regard to which adjunctive mea-
sures, if any, were used. If additional measures were used to
achieve hemostasis at an anastomotic site, the type of
adjunct was recorded. Additional applications of cyanoac-
rylate surgical sealant (investigational device arm only) or
control (control arm only), stitches, or pledgets; adminis-
tration of protamine; or other standards of care for the
center were permitted. Additional applications of cyanoac-
rylate surgical sealant were required to follow the per-
protocol instructions for use, including reclamping, drying
the area, applying the sealant, and waiting 120 seconds
until clamp release. Protamine for reversal of heparin may
have been used after clamp removal in cases of significant
bleeding but should not have been used prophylactically.
Once hemostasis had been achieved at all anastomotic sites
for a patient, closure of the wound was initiated.
Follow-up. Patients receiving AV shunts had their
distal radial pulse assessed upon release from the operating
room, release from the recovery room, discharge from the
hospital, or 48 hours after treatment (whichever was first)
and during posttreatment follow-up assessments at 4 weeks
(7 days) and 12 weeks (7 days). The pulse may have
been assessed by palpation, stethoscope, or Doppler ultra-
sonography. Patients receiving femoral bypass procedures
underwent vascular assessment upon release from the op-
erating room and release from the recovery room. Patients
had their ankle-brachial index measured upon discharge
from the hospital or 48 hours after treatment and during
their follow-up visits at 4 and 12 weeks (7 days). All
patients had their closed treatment sites visually inspected
upon release from the operating room, release from the
recovery room, discharge from the hospital, or 48 hours
after treatment and during post-treatment follow-up visits
at 4 and 12 weeks (7 days).
Primary end point. The primary end point was the
elapsed time between the release of the surgical clamps and
complete sealing of the suture line, which was recorded in
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one anastomotic site treated, the site with the longest time
to hemostasis was used for the primary analysis. Any time to
hemostasis that was10minutes was treated as 10minutes
in the primary analysis.
Secondary efficacy end points. One of the secondary
end points was the proportion of patients achieving hemo-
stasis at t  0 (immediate), 1, 5, or 10 minutes after clamp
release. For femoral bypass patients who hadmore than one
anastomotic site treated, the site with the longest time to
hemostasis was used for these analyses. Another end point
was the frequency of using additional adjunctive measures
to achieve hemostasis. For femoral bypass patients who had
more than one anastomotic site treated, each patient was
classified as having had a specific additional adjunctive
measure or not.
Safety end points. Safety end points included adverse
events and device-related adverse events during the index
hospitalization, from hospital discharge through the
12-week follow-up period, and from the index hospitaliza-
tion through the 12-week follow-up period. Adverse events
that were classified by the clinical investigator as (1) serious
and severe, (2) definitely, probably, or possibly device-
related, or (3) serious or that were not listed in the protocol
as potential adverse events were adjudicated by a data safety
monitor.
Statistical methods. The sample size was based on a
standard deviation of time to hemostasis of 3.8 minutes.15
A total of 150 patients in a 2:1 randomization provided
80% power to reject the noninferiority null hypothesis if the
true mean time to hemostasis was 0.6 minutes faster with
cyanoacrylate surgical sealant than with the control and
80% power to reject the superiority null hypothesis if the
true mean time was 1.9 minutes faster. Baseline compari-
sons were made between treatment groups by t tests for
continuous variables and 2 tests for categorical variables.
All analyses were based on the intent-to-treat data set,
which included all patients in the treatment group to which
the patients were randomized, irrespective of the treatment
they actually received. The primary analysis was an analysis
of variance, which included the effects of treatment group,
procedure (femoral bypass procedures or AV shunt proce-
dures), and study center. Secondary analyses (hemostasis
within various intervals and the use of additional adjunctive
measures to achieve hemostasis) were performed by the
Cochran-Mantel-Haenszel procedure, stratified by proce-
dure and study center. Subgroup analyses were performed
on the primary and secondary efficacy variables by type of
procedure.
Approval. This study was conducted in compliance
with the US Code of Federal Regulations and ethical
principles from the Declaration of Helsinki. Institutional
review boards (United States) or ethics committees (Eu-
rope) at each institution approved the study before study
initiation. Informed consent was obtained from all pa-
tients.RESULTS
Investigational sites and patient accounting. A total
of 151 patients were randomized (2:1) to receive cyanoac-
rylate surgical sealant or the control at 12 sites (10 in the
United States and 2 in Europe). In Europe, all 25 patients
were randomized for femoral bypass procedures (17 to
cyanoacrylate surgical sealant and 8 to the control). In the
United States, 82 patients were randomized for AV shunt
procedures (55 to cyanoacrylate surgical sealant and 27 to
the control), and 44 were randomized for femoral bypass
procedures (29 to cyanoacrylate surgical sealant and 15 to
the control).
All 151 patients completed the operation, and 149
were discharged from the hospital alive. A total of 141
patients completed the 4-week follow-up, and 126 (81 in
the cyanoacrylate surgical sealant group and 45 in the
control group) completed the 12-week follow-up, thus
completing the study. For the 25 patients who did not
complete the study, the reasons were as follows: 5 died, 2
were lost to follow-up, 9 were withdrawn by the investiga-
tor, 4 were withdrawn because of patient choice or inability
to complete the study, 4 had the graft removed, and 1 had
a leg amputated above the knee. Of the 9 patients with-
drawn by the investigator, 7 were in the cyanoacrylate
surgical sealant group and were withdrawn due to graft
removal (n  2), graft occlusion/clotting (n  4), and
ligated graft (n  1), and 2 were in the control group and
were withdrawn as a result of graft occlusion/clotting (n 1)
and explanted graft (n 1).
Baseline demographics. Patient baseline demograph-
ics and clinical characteristics (medical history and baseline
use of anticoagulant and antiplatelet medications) are sum-
Table I. Patient demographics at baseline
Variable
Cyanoacrylate
surgical sealant
(n  101)
Control
(n  50)
P
value
Age, y (mean  SD) 60.8  14.3 61.4  13.9 .83
Sex
Male, n (%) 66 (65.3) 28 (56.0) .26
Female, n (%) 35 (34.7) 22 (44.0)
Procedure
Femoral bypass, n (%) 46 (45.5) 23 (46.0) .96*
Fem-pop, above the
knee 22/38 (57.9) 13/17 (76.5) .43
Fem-pop, below the
knee 7/38 (18.4) 2/17 (11.8)
Fem-fem 4/38 (10.5) 0/17 (0)
Aorto-fem 5/38 (13.2) 2/17 (11.8)
AV access, n (%) 55 (54.5) 27 (54.0)
Upper arm 20 (36.4) 9 (33.3) .93
Lower arm 31 (56.4) 16 (59.3)
Brachial 1 (1.8) 1 (3.7)
Groin 1 (1.8) 0 (0)
Upper leg 1 (1.8) 1 (3.7)
AV, Arteriovenous.
*Femoral bypass vs AV access.
Fem-Pop, femoral to popliteal.marized in Tables I and II, respectively. The statistical
at leas
ore th
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groups were similar at baseline. Preprocedural use of aspirin
and warfarin (P .05) and the proportion of patients with
diabetes (P  .057) were higher in the control group.
When these variables were added to the primary statistical
model, the difference in mean time to hemostasis between
cyanoacrylate surgical sealant and the control increased
from 284 to 301 seconds, thus indicating that they had no
effect on the primary analysis.
Primary end point. The primary outcome measure,
time from clamp release to hemostasis, is shown in Table III.
Results are shown by procedure and anastomotic site in Table
I (online only). As prescribed in the protocol, all times to
hemostasis longer than 10 minutes were replaced by 10
minutes, and for the 69 femoral bypass patients, the anas-
tomotic site with the longest time to hemostasis was used.
The primary efficacy analysis was a test of noninferiority of
Table II. Patient clinical characteristics at baseline, includ
medications taken regularly before enrollment
Characteristic Cyanoacrylate su
Medical history/risk factors
Currently on dialysis
Months on dialysis, mean (range) 23
Hypertension
History of chronic liver disease
History of renal insufficiency
History of renal failure
PVD
Anticoagulant/antiplatelet medications
Aspirin
Clopidogrel
Anti–vitamin K anticoagulants*
Heparin
Cilostazol
Dipyridamole
PVD, Peripheral vascular disease.
*Patients were required to have been off anti–vitamin K anticoagulants for
Data are n (%) unless otherwise noted.
Table III. Difference in mean time from clamp release to
Variable
AV shunt
Cyanoacrylate
surgical sealant
(n  55)
Control
(n  27)
Time to hemostasis (s)
Mean† 77.8 346.6
Difference (95% CI) 268.7
(338.2 to 199.3) (
P value
Noninferiority‡ —
Superiority .001
AV, Arteriovenous; CI, confidence interval.
*The anastomotic site with the longest time was used for femoral bypas
10 minutes.
†Adjusted for study center and type of procedure.
‡Test of the hypothesis that the cyanoacrylate surgical sealant mean is no mthe time to hemostasis for patients treated with cyanoacry-late surgical sealant to within 1 minute of that of patients
treated with the control. The test of noninferiority was
rejected (P  .001), and a test for superiority was per-
formed, which was also significant (P  .001). The mean
time to hemostasis for all procedures was 284 seconds faster
for patients treated with cyanoacrylate surgical sealant than
for those treated with the control.
The time to hemostasis based on the type of procedure
is also shown in Table III. For patients treated with cyano-
acrylate surgical sealant, the mean time to hemostasis was
302 seconds faster than with the control for femoral bypass
patients and was 269 seconds faster for AV access patients.
For both groups, the mean time to hemostasis was faster for
AV shunt procedures than for femoral bypass procedures.
An additional analysis was performed that included the
2-minute polymerization time for cyanoacrylate surgical
sealant in the time to hemostasis. In this analysis, the mean
edical history/risk factors and anticoagulant/antiplatelet
l sealant (n  101) Control (n  50) P value
6.5) 22 (44.0) .77
-168) 16.9 (1-84)
7.1) 42 (84.0) .60
.9) 2 (4.0) 1.0
5.4) 27 (54.0) .87
2.5) 28 (56.0) .68
3.5) 27 (54.0) .95
2.6) 32 (64.0) .013
3.9) 10 (20.0) .33
.9) 12 (24.0) .021
.9) 1 (2.0) .27
.0) 1 (2.0) 1.0
) 1 (2.0) .33
t 4 days before the index procedure.
ostasis between groups
Femoral bypass* All patients*
noacrylate
ical sealant
n  46)
Control
(n  23)
Cyanoacrylate
surgical sealant
(n  101)
Control
(n  50)
159.4 461.9 119.3 403.8
302.4 284.4
.6 to 202.3) (342.9 to 226.0)
— .001
.001 .001
nts with multiple sites treated. All times 10 minutes were replaced by
an 1 minute longer than that of the control.ing m
rgica
47 (4
.5 (0
88 (8
6 (5
56 (5
53 (5
54 (5
43 (4
14 (1
10 (9
7 (6
1 (1
0 (0hem
Cya
surg
(

402
s patietime to hemostasis was 230.7 seconds with cyanoacrylate
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analysis confirmed that time to hemostasis was significantly
faster (191.4 seconds; 95% confidence interval, 139.4-
243.4 seconds) with cyanoacrylate surgical sealant than
with control (P  .001).
Secondary end points. The proportion of patients
who achieved hemostasis within 0 (immediate), 1, 5, and
10 minutes after clamp release is reported by treatment
group and procedure in the Figure and Table II (online
only). The proportion of patients achieving hemostasis
within each of the time intervals was significantly greater for
patients treated with cyanoacrylate surgical sealant than for
those receiving the control (P  .001). Immediate hemo-
stasis was achieved in 54.5% of the patients in the cyanoac-
rylate surgical sealant group vs only 10% of those in the
control group. As with the primary end point, the propor-
tion of patients achieving immediate hemostasis was higher
for AV shunt procedures than for femoral bypass proce-
dures in both treatment groups.
The number of patients who required additional ad-
junctive agents to achieve hemostasis and the type of ad-
junctive agent used is reported in Table IV. Only the
proportion of patients requiring an additional unit of the
assigned treatment was significantly different between
treatment groups (11% for cyanoacrylate surgical sealant
and 30% for the control; P  .001). Similar results were
observed when analysis was performed by procedure.
Safety assessment. All adverse events that occurred
from the index procedure through the 12-week follow-up
are reported by treatment in Table V. The only difference in
event rates that achieved a nominal significance (P  .05)
was hematoma, which occurred in 12% of the control
patients and 2% of the cyanoacrylate surgical sealant pa-
tients. The occurrence of serious adverse events and device-
related adverse events was not significantly different be-
tween treatment groups. The results of vascular assessments
Fig. The percentage of patients achieving hemostasis at t  0
(immediate), 1, 5, and 10 minutes after clamp release is shown for
all procedures by treatment group.were similar in both treatment groups for both procedures.DISCUSSION
The results of this study demonstrate that the family of
cyanoacrylate hemostatic agents, which have proven their
safety and efficacy in topical use,11,12 have now produced a
safe and effective absorbable surgical sealant for internal
use. The data show that the time from clamp release to
complete hemostasis with cyanoacrylate surgical sealant is
shorter than that with oxidized cellulose. In addition, im-
mediate hemostasis was achieved in 55% of the cyanoacry-
late surgical sealant patients, compared with only 10% of
the control patients. Similar safety profiles in both groups
confirm that cyanoacrylate surgical sealant is safe for use in
femoral bypass procedures and AV shunt procedures.
In general, medical risk factors that can affect bleeding
time and hemostasis, such as hypertension and a history of
cerebrovascular accidents, chronic liver disease, or renal
failure, were similar in the two groups at baseline. In the
control group, the proportion with diabetes was marginally
significantly higher, and pre-enrollment use of aspirin and
anti–vitamin K anticoagulants was nominally significantly
higher. However, additional statistical analyses revealed
that these variables did not have a significant effect on the
primary end point and that adjusting for these items actu-
ally increased the difference in time to hemostasis between
groups.
The two potential safety issues that are raised with
cyanoacrylates include carcinogenicity and toxicity. The
issue of carcinogenicity has already been addressed in stud-
ies evaluating the use of internally placed nonabsorbable
cyanoacrylates.16 The cyanoacrylate surgical sealant used in
Table IV. Use of additional adjunctive agents to achieve
hemostasis (all patients and procedures)
Variable
Cyanoacrylate
surgical sealant
(N  101), n (%)
Control
(N  50),
n (%)
P
value*
Patients requiring 1
additional agent† 31 (30.7) 22 (44.0) .08
Additional unit of
assigned treatment 11 (10.9) 15 (30.0) .001
Stitches 7 (6.9) 7 (14.0) .15
Pledgets 0 (0) 0 (0) —
Protamine‡ 7 (6.9) 8 (16.0) .08
Other§ 12 (11.9) 3 (6.0) .22
*Adjusted for study center and procedure.
†The total number of individual agents may exceed the number of patients
who had at least one agent used because patients may have had multiple
agents used and because multiple anastomotic sites were treated in femoral
bypass patients.
‡Protamine was to be administered only after clamp removal in cases of
significant bleeding.
§For the cyanoacrylate surgical sealant group, other adjunctive agents in-
cluded Surgicel (Johnson & Johnson, New Brunswick, NJ; n 3), Surgicel
NuKnit (Johnson& Johnson; n 4), Fibrillar (Johnson& Johnson; n 1),
Gelfoam and thrombin (Pharmacia & Upjohn, Kalamazoo, Mich; n  1),
and manual compression/pressure (n  3). For the control group, other
adjunctive agents included Gelfoam (n  3), Fibrillar (n  1), and Surgicel
Nu Knit (n  3).this study was designed to be absorbed in a controlled
all, se
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this product for internal use has been demonstrated in a
pilot study13 and now in this larger multicenter study.
This study demonstrates the superiority of cyanoacry-
late surgical sealant to oxidized cellulose, which remains the
standard of care; however, it is also interesting to see how it
compares with fibrin sealant or another synthetic sealant.
On the basis of published trials in a similar group of
patients, cyanoacrylate surgical sealant seems to be at least
as effective as these sealants. In a study that compared fibrin
sealant and oxidized cellulose or pressure alone in patients
undergoing AV shunt procedures, the mean time to hemo-
stasis reported for fibrin sealant was 56.3 seconds, and the
Table V. All adverse events occurring from the index proc
Variable
Cyanoacrylate surg
(N  101), n
No. patients with 1 adverse event 69 (68.3
Bleeding complication
Bleeding, procedure 2 (2.0)
Bleeding, postprocedure 2 (2.0)
Coagulopathy 1 (1.0)
Hematoma 2 (2.0)
Pulmonary complication
Atelectasis/pneumonia 0 (0)
Respiratory failure 2 (2.0)
Cardiac complication
Arrhythmia 0 (0)
Myocardial infarction 2 (2.0)
Renal function complication
Renal failure 4 (4.0)
Renal insufficiency 0 (0)
Wound complication*
Dehiscence 5 (5.0)
Lymphocele/lymph fistula 3 (3.0)
Wound infection 8 (7.9)
Neurologic complication
Cerebrovascular accident 0 (0)
Paraplegia/paraparesis 0 (0)
Vascular complication
Edema 5 (5.0)
Occlusion of graft/vessel 12 (11.9
Thrombosis 5 (5.0)
Other complication
Death† 4 (4.0)
Increased temperature 2 (2.0)
Erythema 7 (6.9)
Infection 10 (9.9)
Pain 9 (8.9)
Other 43 (42.6
*Refers to wound complications occurring at the site of the surgical incision
incidence of any wound complication was 13.9% in the cyanoacrylate surgic
not statistically significant (P  .091).
†None of the deaths was reported to be device related.
‡Others were noted as diarrhea, anemia, hyperkalemia, bradycardia, vascular
constipation, visual deficit, ischemic hand, steal syndrome, seroma, intensive
severe hypoglycemia, cellulitis, redness/warmth at incision site, gastrointesti
skin graft right foot, ischemic colitis, pulmonary edema, colon cancer, stenos
chest pain, and excessive bleeding.
§Others were noted as diarrhea, vascular steal syndrome, seroma, subclavia
nonfunctioning hemodialysis catheter, confusion, hyperkalemia, trauma—f
right femoral-popliteal bypass, and infection.proportion of patients achieving immediate hemostasis was54%.17 For AV access patients treated with cyanoacrylate
surgical sealant in this study, we observed a similar unad-
justedmean time to hemostasis (45.7 seconds) and a higher
percentage of patients achieving immediate hemostasis
(73%). Similarly, in a study comparing a polyethylene glycol
sealant with Gelfoam/thrombin (Pharmacia & Upjohn,
Kalamazoo, Mich) in AV access and infra-inguinal bypass
procedures, the proportion of patients achieving immediate
hemostasis with this sealant was 47%,9 which is lower than
the 55% observed with cyanoacrylate surgical sealant in this
study.
Cyanoacrylate surgical sealant has some potential ad-
vantages over fibrin sealants with regard to safety. Fibrin
e through the 12-week follow-up
ealant
Control (N  50), n (%) P value
35 (70.0) .83
0 (0) 1.0
1 (2.0) 1.0
0 (0) 1.0
6 (12.0) .016
1 (2.0) .33
0 (0) 1.0
1 (2.0) .33
0 (0) 1.0
1 (2.0) 1.0
1 (2.0) .33
0 (0) .17
0 (0) .55
2 (4.0) .50
1 (2.0) .33
1 (2.0) .33
4 (8.0) .48
8 (16.0) .48
3 (6.0) 1.0
1 (2.0) 1.0
4 (8.0) .09
1 (2.0) .27
5 (10.0) 1.0
5 (10.0) 1.0
14 (28.0)§ .11
he site where cyanoacrylate surgical sealant or the control was applied. The
ant group and 4% in the control group; the difference between groups was
syndrome, amputation due to tissue loss, vagal dizziness, nausea/vomiting,
nit psychosis, gastrointestinal distress, reddened buttock, epileptic seizure,
eding, hyperglycemia, severe ischemic steal, blister reaction to surgical tape,
nous anastomosis, cholelithiasis, nonhealing wound, contralateral infection,
l, blisters, syncopal episodes, urinary tract infection, itching without rash,
vere nose bleed, serous drainage, increased international normalized ratio,edur
ical s
(%)
)
)
)‡
, not t
al seal
steal
care u
nal ble
is of ve
n steasealants contain derivatives from human plasma and, there-
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November 20061008 Lumsden and Heymanfore, have a potential viral risk.18 In addition, most fibrin
sealants contain a bovine thrombin component, which can
be immunogenic.18 Although the potential risk is low, use
of a synthetic sealant such as cyanoacrylate surgical sealant
eliminates the risk. There is also a potential issue with
patency of the anastomosis. There is evidence that sealants
containing thrombin can adversely affect the patency of
microvascular anastomoses; therefore, sealants that do not
contain thrombin are recommended.19 This could also
apply to the patency of nonmicrovascular grafts, and the
potential risk could be avoided by using non–thrombin-
containing sealants, such as cyanoacrylate surgical sealant.
For AV dialysis grafts, there is already a concern about
thrombosis and anastomotic stenosis when ePTFE grafts
are used, and additional risk could be avoided by using a
sealant without thrombin.20,21
Cyanoacrylate surgical sealant has some characteristics
that make it particularly useful and reliable for the surgeon.
It can be stored at room temperature, can be easily and
rapidly prepared in the applicator device, and is easy to
apply. In addition, the sealant is mechanical and functions
independently of the body’s clottingmechanism. The avail-
ability of an effective surgical sealant such as cyanoacrylate
surgical sealant means that vascular surgery is moving to-
ward the ideal situation in which anastomotic bleeding is
an unnecessary, unacceptable consequence of joining an
ePTFE graft to an artery and leads to the possibility of
performing sutureless anastomoses. Future uses of cyano-
acrylate surgical sealant could include other areas of
vascular surgery where there is a critical need for good
hemostatic control, such as carotid endarterectomy and
abdominal aortic aneurysm repair, especially with ePTFE
grafts. It could also be used to give added security to the
surgeon when the vascular procedure is being undertaken
laparoscopically, as is increasingly becoming the case. Be-
yond the vascular anastomosis field, a strong effective sur-
gical sealant could also be useful in other areas such as glue
aortoplasty or surgery to repair complicated cardiac defects.
CONCLUSION
This study demonstrates that cyanoacrylate surgical
sealant is highly effective at reducing the time to hemostasis
in AV shunt and femoral bypass procedures and is safe for
internal use. Immediate hemostasis was achieved in more
than 50% of the patients, and the need for additional
adjunctive agents was reduced. Cyanoacrylate surgical seal-
ant is an easy-to-use vascular sealant with good safety and
efficacy that significantly decreases anastomotic bleeding in
vascular surgery.
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at www.jvascsurg.org.INVITED COMMENTARYR. James Valentine, MD, Dallas, Texas
Experienced vascular surgeons recognize the value of topical
hemostatic agents to treat anastomotic bleeding. Regardless of
whether these agents actually contribute to local hemostasis or
merely allow time for full heparin reversal and activation of the
patient’s own clotting factors, we all use them. Numerous options
are currently available, and every surgeon has a favorite. However,
no agent has emerged as clearly superior in terms of rapid hemo-
stasis, ease of use, low cost, and minimal toxicity.
Enter cyanoacrylate, the holy grail of topical sealants. As
shown in the present study, this agent stops anastomotic bleeding
at the source, just like a self-sealing tire. By creating a mechanical
seal at leak sites, cyanoacrylate works independently of the patient’s
ability to form clot. Compared with the popular oxidized cellulose
alternative, cyanoacrylate achieves more rapid hemostasis at all
time intervals after clamp release. And it does this without any
measurable increase in complications.
Based on the elegant methods and statistical support of the
present study, the evidence for the superiority of cyanoacrylate
seems irrefutable. However, there are a number of problems with
the study design that should temper our enthusiasm beyond the
fact the agent is not currently on the market. The first issue is that
the study groups may not have been adequately matched. Signifi-
cantly more controls received aspirin, and more controls had takenulation effects of warfarin should have resolved within the 4 days of
discontinuation mandated by the inclusion criteria, we do not
know how many subjects were over-anticoagulated, and we have
no tests to ensure the absence of a residual anticoagulation effect.
A second concern is that the procedures were not standard-
ized. Expanded polytetrafluoroethylene grafts were not uniform,
and we do not know, for example, how many patients received
standard-wall vs thin-wall grafts. Intraoperative heparin dosing was
not standardized, nor was it monitored with the activated clotting
time. The use of protamine was left entirely up to the decision of
the surgeon, who was not blinded to the type of agent being used.
Although patients receiving cyanoacrylate had a mandatory 2-minute
wait time before clamps were removed, this was not the case for the
controls. A 2-minute exposure to microscopic amounts of bloodmay
have improved the hemostatic action of the control agent.
Despite these criticisms, there is much to commend this study.
It is prospective, randomized, and adequately powered. The results
are clear: to treat anastomotic bleeding, cyanoacrylate achieves
faster hemostasis than oxidized cellulose. Cyanoacrylate is easy to
apply and appears to have low toxicity. The present analysis is
certainly provocative, and the study agent is very promising; how-
ever, further experience with cyanoacrylate is needed before we can
say that it is superior to other agents.
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Time to hemostasis* Cyanoacrylate surgical sealant Control
Femoral bypass: proximal site (n) 45† 23
Mean  SD (s) 174.4  223.7 426.6  199.6
Range (s) 0-600 0-600
Femoral bypass: distal site (n) 44† 23
Mean  SD (s) 37.6  72.6 323.2  261.3
Range (s) 0-273 0-600
Femoral bypass: second distal site (n) 5 2
Mean  SD (s) 42.2  74.1 510.0  127.3
Range (s) 0-171 420-600
Femoral bypass: site with longest time (n) 46 23
Mean  SD (s) 194.4  212.8 505.0  152.3
Range (s) 0-600 70-600
AV access for hemodialysis (n) 55 27
Mean  SD (s) 45.7  105.2 298.0  231.1
Range (s) 0-600 0-600
AV, Arteriovenous.
*All times 10 minutes were replaced by 10 minutes.
†One patient had no proximal site treated but had two distal sites treated, and two patients had one proximal site treated and no distal site.Table II, online only. Proportion of patients achieving
hemostasis in minute intervals by treatment group and
procedure
Variable
Cyanoacrylate
surgical sealant
(n  101)
Control
(n  50) P value*
AV shunt†
0 (immediate) 40 (72.7) 5 (18.5) .001
0-1 min 43 (78.2) 7 (25.9) .001
0-5 min 53 (96.4) 13 (48.2) .001
0-10 min 54 (98.2) 21 (77.8) .001
10 min 1 (1.8) 6 (22.2) .001
Femoral bypass†
0 (immediate) 15 (32.6) 0 (0) .003
0-1 min 18 (39.1) 0 (0) .001
0-5 min 36 (78.3) 3 (13.0) .001
0-10 min 40 (87.0) 8 (34.8) .001
10 min 6 (13.0) 15 (65.2) .001
All patients
0 (immediate) 55 (54.5) 5 (10.0) .001
0-1 min 61 (60.4) 7 (14.0) .001
0-5 min 89 (88.1) 16 (32.0) .001
0-10 min 94 (93.1) 29 (58.0) .001
10 min 7 (6.9) 21 (42.0) .001
AV, Arteriovenous.
Data are n (%).
*Adjusted for study center.
†The anastomotic site with the longest time was used for femoral bypass
patients with multiple sites treated.
